TB-500
TB-500 is supplied lyophilized at the stated quantity per vial, sealed under nitrogen. Purity ≥99% (HPLC). Each lot is released with a Certificate of Analysis. For laboratory research use only.
TB-500
Background
TB-500 is the research designation for a synthetic fragment corresponding to the actin-binding domain of thymosin beta-4 (Tbeta4), a 43-amino-acid G-actin-sequestering peptide present in most mammalian cells. Research interest centers on its role in cytoskeletal regulation, cell migration, and angiogenesis, with the actin-binding sequence proposed as a key driver of the molecule's reparative activity in model systems.
Preclinical investigations have examined thymosin beta-4 and its fragments in dermal, corneal, and cardiac tissue-repair models, as well as in studies of vascular formation and inflammation modulation. The evidence base is predominantly experimental; TB-500 itself is not a clinically approved therapeutic.
Selected literature
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine. 2005;11(9):421-429.
- Crockford D, et al. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Annals of the New York Academy of Sciences. 2010;1194:179-189.
- Goldstein AL, Kleinman HK. Advances in the basic and clinical applications of thymosin beta4. Expert Opinion on Biological Therapy. 2015;15(sup1):S139-S145.
References are provided for scientific context only. Citation does not imply endorsement of any use, nor a claim of safety or efficacy. Findings frequently derive from in-vitro or animal models.
Trademarks & attribution
TB-500 is a research designation for a synthetic thymosin beta-4 fragment. It is not a registered pharmaceutical trademark and has no approved drug product. Supplied as reference material only.
